Navigation Links
Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
Date:12/19/2011

CARLSBAD, Calif., Dec. 19, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA).  SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality.  Isis is developing ISIS-SMNRx as a potential treatment for all Types of SMA.

"SMA is a devastating disease that leads to the loss of motor neurons resulting in muscle weakness and respiratory failure in children.  The genetic cause of this disease is well understood, but there are currently no effective disease-modifying therapies.  Currently, treatment of SMA is entirely symptomatic and focuses on preserving muscle strength and lung function by physical therapy and assisted ventilation.  This supportive approach has improved the natural history of SMA by extending life expectancy, but muscle weakness and atrophy are not affected.  A disease-modifying drug like ISIS-SMNRx that specifically targets the cause of the disease could, for the first time, restore muscle strength and respiratory function and dramatically improve the children's function and quality of life," said Darryl C. De Vivo, M.D., Sidney Carter Professor of Neurology and Pediatrics and Co-Director of the Motor Neuron Center at Columbia University Medical Center.

SMA is a severe genetic disease that affects approximately 30,000 – 35,000 patients in the United States, Europe and Japan.  One in 50 people, approximately 6 million people in the United States, are carriers of the SMA gene.  Carriers experience no symptoms and do not develop the disease, however, when both parents are carriers, there is a one in four chance that their child will have SMA.  SMA is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene leading to a decrease in
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
3. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
4. Spring Creek Healthcare Systems Initiates Strategy to Partner and License DelRX Patents
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
6. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
7. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
8. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
11. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... 2010 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today reported results for the third ... grew 6% to $13.2 million reflecting core product (IOLs ... decrease in defocused product revenue as compared to the ...
... Nov. 2, 2010 Kensey Nash Corporation (Nasdaq: ... investor conferences in November.   Michael Celano, ... presentation, at the Oppenheimer 21st Annual Healthcare Conference at ... at 2:10 p.m. (ET).  To hear the live webcast ...
Cached Medicine Technology:STAAR Surgical Reports Continued Double Digit Core Revenue Growth 2STAAR Surgical Reports Continued Double Digit Core Revenue Growth 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 4STAAR Surgical Reports Continued Double Digit Core Revenue Growth 5STAAR Surgical Reports Continued Double Digit Core Revenue Growth 6STAAR Surgical Reports Continued Double Digit Core Revenue Growth 7STAAR Surgical Reports Continued Double Digit Core Revenue Growth 8STAAR Surgical Reports Continued Double Digit Core Revenue Growth 9STAAR Surgical Reports Continued Double Digit Core Revenue Growth 10STAAR Surgical Reports Continued Double Digit Core Revenue Growth 11STAAR Surgical Reports Continued Double Digit Core Revenue Growth 12STAAR Surgical Reports Continued Double Digit Core Revenue Growth 13STAAR Surgical Reports Continued Double Digit Core Revenue Growth 14STAAR Surgical Reports Continued Double Digit Core Revenue Growth 15STAAR Surgical Reports Continued Double Digit Core Revenue Growth 16STAAR Surgical Reports Continued Double Digit Core Revenue Growth 17
(Date:7/10/2014)... For decades, health-conscious people around the globe have taken ... this was one of the paths to good health ... trials of antioxidant supplements have repeatedly dashed the hopes ... cancer risk. Virtually all such trials have failed ... fact, in several trials antioxidant supplementation has been linked ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... you think winning is one of the key determinants that ... with other mental bonuses ranked near the bottom of 81 ... 11 big fun factors, according to a new study. Despite ... comes to the "fun" factor, very little research had been ... elusive conceptuntil now. , The results of this study might ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
... 27 Attorney General Michael,B. Mukasey will deliver the ... Ceremony and remarks on Justice,Department nationwide efforts to combat ... be held on WEDNESDAY, MAY 28, 2008., WHO: ... WHEN: WEDNESDAY, MAY 28, 2008, 1:00 P.M. ...
... Fla. Once heralded as a promising obesity treatment, ... discovered overweight patients were resistant to its effects. But ... seems to revive the hormones ability to fight fat ... The combination of leptin and a modest dose of ...
... Finer Senior Living Expected in Coming Years, SANTA ... and scenery at Varenna. Oakmont Senior Living LLC did ... that benefits from 25 years,of experience in every facet ... new continuing care residential community sets a grand,and unparalleled ...
... is not associated with a reduced risk of prostate ... 27 in the Journal of the National Cancer ... of vitamin D may reduce the risk of prostate ... have reported inconsistent results. , In a nested case-control ...
... finds evidence of slight link between higher concentrations, aggressive ... Men with a high blood concentration of vitamin D ... Cancer Institute researchers report. , Previous laboratory studies had ... prostate cancer risk, but epidemiological studies of that association ...
... completely unexpected way that the brain repairs nerve damage, wherein ... neurons. , Astrocytes are a type of support cell in ... is to chew up damaged nerves during brain injury and ... Roger Chung and colleagues have now found that astrocytes have ...
Cached Medicine News:Health News:Combining exercise with hormone could prevent weight gain 2Health News:Combining exercise with hormone could prevent weight gain 3Health News:Sonoma Developer Oakmount Senior Living Marries Architecture With Nature to Recreate Tuscany at Varenna 2Health News:Sonoma Developer Oakmount Senior Living Marries Architecture With Nature to Recreate Tuscany at Varenna 3Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Vitamin D Status Not Associated With Lower Prostate Risk 2
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
... into comfortable holder, measuring switch is ... is performed., ,Large display of ... surroundings, back light automatically turns on ... compact contour and design provide steady, ...
Medicine Products: